NUCALA® ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 44 | 多発血管炎性肉芽腫症 | 1 |
44. 多発血管炎性肉芽腫症
臨床試験数 : 98 / 薬物数 : 108 - (DrugBank : 28) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 81
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05353179 (ClinicalTrials.gov) | June 2022 | 11/4/2022 | Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers | Phase I, Single-center, Randomized, Double-blind, Single-dose, Parallel Comparison of Pharmacokinetic and Safety Similarities Between Meperizumab Injection and NUCALA® in Healthy Male Volunteers | Granulomatosis With Polyangiitis;Hemophagocytic Syndrome | Drug: Meperizumab injection;Drug: NUCALA® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NULL | Not yet recruiting | 18 Years | 55 Years | Male | 88 | Early Phase 1 | China |